|
May 9
|
uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 7
|
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Dec 19
|
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
|
|
Dec 19
|
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
|
|
Dec 12
|
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 2
|
Shareholders in uniQure (NASDAQ:QURE) are in the red if they invested three years ago
|
|
Nov 29
|
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
|
|
Aug 6
|
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
|
|
Jun 22
|
Why uniQure Stock Cratered This Week
|
|
Jun 22
|
uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
|
|
Jun 21
|
Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy
|
|
Jun 21
|
Why uniQure Stock Is Crashing Today
|
|
Jun 21
|
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
|
|
Jun 20
|
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
|
|
Jun 20
|
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
|
|
May 2
|
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
|
|
May 2
|
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|